Aine Miller is Senior Vice President, Development and Head of Ireland Office at Theravance Biopharma Inc., where she spearheads the company's global development strategy and oversees operations from the Dublin headquarters. With more than 25 years of experience in the biopharmaceutical industry, Miller drives clinical development programs for Theravance's innovative respiratory medicine pipeline, including key assets like nebulized treprostinil for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Her leadership ensures efficient progression of late-stage trials and regulatory submissions, positioning the company to deliver transformative therapies to patients with unmet needs in respiratory diseases. Prior to joining Theravance in 2019, Miller served as Vice President, Regulatory Affairs at Alkermes plc, where she led regulatory strategies for neuroscience and oncology portfolios, securing multiple FDA approvals and supporting global market access. She spent over two decades at Elan Corporation, advancing from regulatory roles to Vice President of Regulatory Affairs and Chemistry, Manufacturing, and Controls (CMC), contributing to the successful development and commercialization of therapies such as Tysabri for multiple sclerosis and Prialt for severe chronic pain. Aine Miller's achievements include navigating complex regulatory pathways across Europe, the US, and beyond, fostering cross-functional teams to accelerate drug approvals, and building robust development infrastructures. A qualified pharmacist with a BSc in Microbiology from University College Galway (now University of Galway), she brings deep scientific expertise and strategic insight to Theravance Biopharma's mission of addressing serious diseases through inhaled therapeutics.